Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gomez; Phuong Dinh; Karine Kauria; Veerie Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horvath; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Gunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymur Probachai; Lajos Pusztai

doi:10.1016/S0140-6736(11)61847-3

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gomez, Phuong Dinh, Karine Kauria, Veerie Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horvath, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Gunz, Joo Hyuk Sohn, Vladimir SemiglazovGuillermo Lerzo, Marketa Palacova, Volodymur Probachai, Lajos Pusztai

Research output: Contribution to journal › Article

844 Citations (Scopus)

Original language	English
Pages (from-to)	663-640
Journal	The Lancet
Volume	379
Issue number	9816
DOIs	https://doi.org/10.1016/S0140-6736(11)61847-3
Publication status	Published - 2012

Cite this

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., ... Pusztai, L. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3

Baselga, Jose ; Bradbury, Ian ; Eidtmann, Holger ; Di Cosimo, Serena ; de Azambuja, Evandro ; Aura, Claudia ; Gomez, Henry ; Dinh, Phuong ; Kauria, Karine ; Van Dooren, Veerie ; Aktan, Gursel ; Goldhirsch, Aron ; Chang, Tsai-Wang ; Horvath, Zsolt ; Coccia-Portugal, Maria ; Domont, Julien ; Tseng, Ling-Min ; Gunz, Georg ; Hyuk Sohn, Joo ; Semiglazov, Vladimir ; Lerzo, Guillermo ; Palacova, Marketa ; Probachai, Volodymur ; Pusztai, Lajos. / Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. In: The Lancet. 2012 ; Vol. 379, No. 9816. pp. 663-640.

@article{4631419bc91847438444c0c62966e457,

title = "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial",

author = "Jose Baselga and Ian Bradbury and Holger Eidtmann and {Di Cosimo}, Serena and {de Azambuja}, Evandro and Claudia Aura and Henry Gomez and Phuong Dinh and Karine Kauria and {Van Dooren}, Veerie and Gursel Aktan and Aron Goldhirsch and Tsai-Wang Chang and Zsolt Horvath and Maria Coccia-Portugal and Julien Domont and Ling-Min Tseng and Georg Gunz and {Hyuk Sohn}, Joo and Vladimir Semiglazov and Guillermo Lerzo and Marketa Palacova and Volodymur Probachai and Lajos Pusztai",

year = "2012",

doi = "10.1016/S0140-6736(11)61847-3",

language = "English",

volume = "379",

pages = "663--640",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9816",

}

Baselga, J, Bradbury, I, Eidtmann, H, Di Cosimo, S, de Azambuja, E, Aura, C, Gomez, H, Dinh, P, Kauria, K, Van Dooren, V, Aktan, G, Goldhirsch, A, Chang, T-W, Horvath, Z, Coccia-Portugal, M, Domont, J, Tseng, L-M, Gunz, G, Hyuk Sohn, J, Semiglazov, V, Lerzo, G, Palacova, M, Probachai, V & Pusztai, L 2012, 'Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial', The Lancet, vol. 379, no. 9816, pp. 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. / Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Kauria, Karine; Van Dooren, Veerie; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Gunz, Georg; Hyuk Sohn, Joo; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymur; Pusztai, Lajos.

In: The Lancet, Vol. 379, No. 9816, 2012, p. 663-640.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

AU - Baselga, Jose

AU - Bradbury, Ian

AU - Eidtmann, Holger

AU - Di Cosimo, Serena

AU - de Azambuja, Evandro

AU - Aura, Claudia

AU - Gomez, Henry

AU - Dinh, Phuong

AU - Kauria, Karine

AU - Van Dooren, Veerie

AU - Aktan, Gursel

AU - Goldhirsch, Aron

AU - Chang, Tsai-Wang

AU - Horvath, Zsolt

AU - Coccia-Portugal, Maria

AU - Domont, Julien

AU - Tseng, Ling-Min

AU - Gunz, Georg

AU - Hyuk Sohn, Joo

AU - Semiglazov, Vladimir

AU - Lerzo, Guillermo

AU - Palacova, Marketa

AU - Probachai, Volodymur

AU - Pusztai, Lajos

PY - 2012

Y1 - 2012

U2 - 10.1016/S0140-6736(11)61847-3

DO - 10.1016/S0140-6736(11)61847-3

M3 - Article

VL - 379

SP - 663

EP - 640

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9816

ER -

Access to Document

10.1016/S0140-6736(11)61847-3

http://www.sciencedirect.com/science/article/pii/S0140673611618473